[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU97100179A - MONOCLONAL ANTIBODY AGAINST CD44V6 - Google Patents

MONOCLONAL ANTIBODY AGAINST CD44V6

Info

Publication number
RU97100179A
RU97100179A RU97100179/04A RU97100179A RU97100179A RU 97100179 A RU97100179 A RU 97100179A RU 97100179/04 A RU97100179/04 A RU 97100179/04A RU 97100179 A RU97100179 A RU 97100179A RU 97100179 A RU97100179 A RU 97100179A
Authority
RU
Russia
Prior art keywords
antibody
antibody molecule
molecule
molecule according
paragraphs
Prior art date
Application number
RU97100179/04A
Other languages
Russian (ru)
Other versions
RU2204606C2 (en
Inventor
Р.Адольф Гюнтер
Патцельт Эрик
Original Assignee
Берингер Ингельгейм Интернациональ ГмбХ
Форшунгсцентрум Карлсруе Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19944431297 external-priority patent/DE4431297A1/en
Application filed by Берингер Ингельгейм Интернациональ ГмбХ, Форшунгсцентрум Карлсруе Гмбх filed Critical Берингер Ингельгейм Интернациональ ГмбХ
Publication of RU97100179A publication Critical patent/RU97100179A/en
Application granted granted Critical
Publication of RU2204606C2 publication Critical patent/RU2204606C2/en

Links

Claims (17)

1. Антитело против эпитопа в аминокислотной последовательности, которая кодируется вариабельным экзоном v6 гена CD44, отличающееся тем, что оно представляет собой антитело VFF-18, которое образуется от линии клеток гибридомы, депонированной под номером DSM АСС2174.1. The antibody against the epitope in the amino acid sequence that is encoded by the variable exon v6 of the CD44 gene, characterized in that it is a VFF-18 antibody, which is formed from a hybridoma cell line deposited under DSM number ACC2174. 2. Линия клеток гибридомы, депонированная под номером DSM АСС2174. 2. The hybridoma cell line deposited under DSM number ACC2174. 3. Молекула антитела, полученная путем химической или ферментативной модификации антитела по п. 1. 3. An antibody molecule obtained by chemical or enzymatic modification of an antibody according to claim 1. 4. Молекула антитела по п. 3, отличающаяся тем, что она является фрагментом антитела по п. 1. 4. The antibody molecule according to p. 3, characterized in that it is a fragment of the antibody according to p. 1. 5. Молекула антитела по п. 4, отличающаяся тем, что она является фрагментом Fab или F(ab')2.5. The antibody molecule according to p. 4, characterized in that it is a Fab or F (ab ') 2 fragment. 6. Молекула антитела по п. 3, отличающаяся тем, что антитело связано с другой молекулой. 6. The antibody molecule according to p. 3, characterized in that the antibody is associated with another molecule. 7. Молекула антитела по п. 6, отличающаяся тем, что другая молекула является полипептидом. 7. The antibody molecule according to claim 6, characterized in that the other molecule is a polypeptide. 8. Молекула антитела по одному из пп. 3 - 5, отличающаяся тем, что она связана с радиоактивным изотопом. 8. The antibody molecule according to one of paragraphs. 3 to 5, characterized in that it is associated with a radioactive isotope. 9. Рекомбинантная молекула антитела с идиотипом антитела по п. 1. 9. The recombinant antibody molecule with the idiotype of the antibody according to claim 1. 10. Рекомбинантная молекула антитела по п. 9, отличающаяся тем, что она является химерной, приближенной к человеческой, одноцепочечной или полученной путем сцепления цепей молекулой антитела. 10. The recombinant antibody molecule according to claim 9, characterized in that it is chimeric, close to human, single-stranded or obtained by chain linking an antibody molecule. 11. Рекомбинантная молекула антитела по п. 9 или 10, отличающаяся тем, что она соединена с другой молекулой или с радиоактивным изотопом. 11. The recombinant antibody molecule according to claim 9 or 10, characterized in that it is connected to another molecule or to a radioactive isotope. 12. Молекула антитела, распознающая такой же эпитоп, как антитело по п. 1. 12. An antibody molecule that recognizes the same epitope as the antibody of claim 1. 13. Применение антитела или молекулы антитела по одному из пп. 1 или 3 - 12 для способов диагностики вне тел человека или животных. 13. The use of antibodies or antibody molecules according to one of paragraphs. 1 or 3 - 12 for diagnostic methods outside the bodies of humans or animals. 14. Применение по п. 13, отличающееся тем, что способ представляет из себя ферментный иммуносорбентный анализ или радиоиммунный анализ. 14. The use of claim 13, wherein the method is an enzyme immunosorbent assay or a radioimmune assay. 15. Применение по п. 13, отличающееся тем, что способ является иммуногистохимическим. 15. The application of claim 13, wherein the method is immunohistochemical. 16. Антитело или молекула антитела по одному из пп. 1 или 3 - 12 для фармацевтического использования. 16. The antibody or antibody molecule according to one of claims. 1 or 3 to 12 for pharmaceutical use. 17. Применение антитела или молекулы антитела по одному из пп. 1 или 3 - 11 для получения средства для диагностики in vivo. 17. The use of antibodies or antibody molecules according to one of paragraphs. 1 or 3 to 11 to obtain an in vivo diagnostic agent.
RU97100179/13A 1994-06-08 1995-06-02 Antibody vff-18 and its analogues RU2204606C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEP4419913.9 1994-06-08
DE4419913 1994-06-08
DEP4431297.0 1994-09-02
DE19944431297 DE4431297A1 (en) 1994-09-02 1994-09-02 Antibody VFF-18 specific for epitope encoded by exon v6 of CD44

Publications (2)

Publication Number Publication Date
RU97100179A true RU97100179A (en) 1999-03-20
RU2204606C2 RU2204606C2 (en) 2003-05-20

Family

ID=25937246

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97100179/13A RU2204606C2 (en) 1994-06-08 1995-06-02 Antibody vff-18 and its analogues

Country Status (28)

Country Link
US (1) US5916561A (en)
EP (1) EP0765343B1 (en)
JP (2) JP3387929B2 (en)
KR (2) KR100379217B1 (en)
CN (1) CN1125083C (en)
AT (1) ATE197592T1 (en)
BG (1) BG64181B1 (en)
BR (1) BR9507964A (en)
CA (1) CA2192370A1 (en)
CO (1) CO4410258A1 (en)
CZ (1) CZ291274B6 (en)
DE (1) DE59508864D1 (en)
DK (1) DK0765343T3 (en)
ES (1) ES2151603T3 (en)
FI (1) FI964845A (en)
GR (1) GR3035388T3 (en)
HK (1) HK1011697A1 (en)
HU (1) HU220168B (en)
NO (1) NO317948B1 (en)
NZ (1) NZ288224A (en)
PL (1) PL190897B1 (en)
PT (1) PT765343E (en)
RO (1) RO118753B1 (en)
RU (1) RU2204606C2 (en)
SI (1) SI0765343T1 (en)
SK (1) SK282649B6 (en)
UA (1) UA58482C2 (en)
WO (1) WO1995033771A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY24389A1 (en) * 1995-12-06 2001-10-25 Karlsruhe Forschzent PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA
AU1672097A (en) * 1996-02-15 1997-09-02 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel
DE19648209A1 (en) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Procedure for tumor cell depletion of CD34-positive cells
DE19708713C2 (en) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Use of preparations containing anti-CD44 antibodies for the treatment of certain tumors and for the suppression of immune reactions
CA2329776C (en) * 1998-06-08 2009-02-10 Fuso Pharmaceutical Industries, Ltd. Antibody against lar phosphatase subunit
CA2332310C (en) * 1998-07-10 2007-06-05 Fuso Pharmaceutical Industries, Ltd. Antibody against protein tyrosine phosphatase intracellular domains
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
WO2002094879A1 (en) * 2001-05-18 2002-11-28 Boehringer Ingelheim International Gmbh Antibodies specific for cd44v6
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
CA2458565A1 (en) * 2001-08-24 2003-03-06 Staffan Stroemblad New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
US20040120949A1 (en) * 2002-11-08 2004-06-24 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
EP2467401B1 (en) * 2009-08-19 2017-01-18 Merck Patent GmbH Antibodies for the detection of integrin complexes in ffpe material
CN102337298B (en) * 2011-08-19 2013-11-06 黄开红 Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof
PL2886126T3 (en) 2013-12-23 2017-11-30 Exchange Imaging Technologies Gmbh Nanoparticle conjugated to CD44 binding peptides
JP2021519608A (en) * 2018-02-22 2021-08-12 マルティチュード・インコーポレーテッド Therapeutic antibodies and their use
CN109593125A (en) * 2018-12-12 2019-04-09 深圳市龙华区人民医院 Antigen epitope polypeptide CD44-P1 and its application based on prostate cancer stem cells marker CD44

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012631A1 (en) * 1992-11-20 1994-06-09 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
ES2110764T3 (en) * 1993-06-18 1998-02-16 Biotie Therapies Oy DIAGNOSTIC COMPOSITIONS AND METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44V6.
EP0767379A1 (en) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Method for the diagnosis and analysis of colon carcinoma

Similar Documents

Publication Publication Date Title
RU97100179A (en) MONOCLONAL ANTIBODY AGAINST CD44V6
AU617367B2 (en) Recombinant antibody
US6218149B1 (en) Antibodies having modified carbohydrate content and methods of preparation and use
AU2004220156B2 (en) Monoclonal antibody and hybridoma producing the same
JPH03501440A (en) immunoreactive heterochain antibody
CA2368965A1 (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
SK154896A3 (en) Monoclonal antibody active against cd44v6 and their use
DE60014124D1 (en) ANTIBODIES SPECIFIC TO FULLERENE
US20020197694A1 (en) Conjugates of reduced antibodies and biomolecules
JP2831852B2 (en) Cell surface proteins expressed on human thymic cortical cells and uses thereof
US5051371A (en) Modified β2 -microglobulin
US5175113A (en) Modified β2 -microglobulin
MXPA01002248A (en) High-affinity antibodies.
CN112898430A (en) Binding protein of CA242, application thereof, detection method and kit
Leibiger et al. Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma
KR860006989A (en) Monoclonal Antibodies Against Atrial, Sodium Diuretic Peptides Of The Human Body
JP5588585B2 (en) Antibodies against prothrombin fragment F1 + 2, their production and use
JP5770092B2 (en) Monoclonal antibody against human HIG1 polypeptide
JP5123627B2 (en) Monoclonal antibody specific for heparan sulfate from dentin
Perdivara et al. Determination of primary structure and microheterogeneity of a β-amyloid plaque-specific antibody using high-performance LC–tandem mass spectrometry
Van Leuven et al. Mapping of structure-function relationships in proteins with a panel of monoclonal antibodies: A study on human α2 macroglobulin
CN117659171B (en) Anti-HBeAg antibody or functional fragment thereof, reagent for detecting HBeAg and kit
KR102511816B1 (en) c-Myc peptide specific antibody and uses thereof
JPH07309900A (en) Anti-human procathepsin b monoclonal antibody, hybridoma producting the same and assay of human procathepsin b or human cathepsin b using the same
CN114716547A (en) Binding protein comprising antigen binding domain and production method and application thereof